

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Jerel Davis</u> <hr/> (Last) (First) (Middle) <u>C/O TURNSTONE BIOLOGICS CORP.</u> <u>9310 ATHENA CIRCLE, SUITE 300</u> <hr/> (Street) <u>LA JOLLA CA 92037</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Turnstone Biologics Corp. [TSBX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/25/2023</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/25/2023		C		2,528,864	A	(1)	2,528,864	I	By Versant Venture Capital V, L.P. ⁽²⁾
Common Stock	07/25/2023		C		192,458	A	(1)	192,458	I	By Versant Venture Capital V (Canada) LP ⁽³⁾
Common Stock	07/25/2023		C		84,313	A	(1)	84,313	I	By Versant Ophthalmic Affiliates Fund I, L.P. ⁽⁴⁾
Common Stock	07/25/2023		C		76,067	A	(1)	76,067	I	By Versant Affiliates Fund V, L.P. ⁽⁵⁾
Common Stock	07/25/2023		C		274,990	A	(1)	274,990	I	By Versant Vantage II, L.P. ⁽⁶⁾
Common Stock	07/25/2023		P		197,458	A	\$12	2,726,322	I	By Versant Venture Capital V, L.P. ⁽²⁾
Common Stock	07/25/2023		P		15,028	A	\$12	207,486	I	By Versant Venture Capital V (Canada) LP ⁽³⁾
Common Stock	07/25/2023		P		6,575	A	\$12	90,888	I	By Versant Ophthalmic Affiliates Fund I, L.P. ⁽⁴⁾
Common Stock	07/25/2023		P		5,939	A	\$12	82,006	I	By Versant Affiliates Fund V, L.P. ⁽⁵⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	07/25/2023		C			7,897,999	(1)	(1)	Common Stock	988,832	\$0.00	0	I	By Versant Venture Capital V, L.P. ⁽²⁾
Series A Preferred Stock	(1)	07/25/2023		C			601,077	(1)	(1)	Common Stock	75,255	\$0.00	0	I	By Versant Venture Capital V (Canada) LP ⁽³⁾
Series A Preferred Stock	(1)	07/25/2023		C			263,349	(1)	(1)	Common Stock	32,971	\$0.00	0	I	By Versant Ophthalmic Affiliates Fund I, L.P. ⁽⁴⁾
Series A Preferred Stock	(1)	07/25/2023		C			237,575	(1)	(1)	Common Stock	29,744	\$0.00	0	I	By Versant Affiliates Fund V, L.P. ⁽⁵⁾
Series B-1 Preferred Stock	(1)	07/25/2023		C			3,530,789	(1)	(1)	Common Stock	442,055	\$0.00	0	I	By Versant Venture Capital V, L.P. ⁽²⁾
Series B-1 Preferred Stock	(1)	07/25/2023		C			268,711	(1)	(1)	Common Stock	33,642	\$0.00	0	I	By Versant Venture Capital V (Canada) LP ⁽³⁾
Series B-1 Preferred Stock	(1)	07/25/2023		C			117,730	(1)	(1)	Common Stock	14,739	\$0.00	0	I	By Versant Ophthalmic Affiliates Fund I, L.P. ⁽⁴⁾
Series B-1 Preferred Stock	(1)	07/25/2023		C			106,208	(1)	(1)	Common Stock	13,297	\$0.00	0	I	By Versant Affiliates Fund V, L.P. ⁽⁵⁾
Series B-2 Preferred Stock	(1)	07/25/2023		C			7,650,043	(1)	(1)	Common Stock	957,787	\$0.00	0	I	By Versant Venture Capital V, L.P. ⁽²⁾
Series B-2 Preferred Stock	(1)	07/25/2023		C			582,206	(1)	(1)	Common Stock	72,892	\$0.00	0	I	By Versant Venture Capital V (Canada) LP ⁽³⁾
Series B-2 Preferred Stock	(1)	07/25/2023		C			255,081	(1)	(1)	Common Stock	31,936	\$0.00	0	I	By Versant Ophthalmic Affiliates Fund I, L.P. ⁽⁴⁾
Series B-2 Preferred Stock	(1)	07/25/2023		C			230,117	(1)	(1)	Common Stock	28,810	\$0.00	0	I	By Versant Affiliates Fund V, L.P. ⁽⁵⁾
Series C Preferred Stock	(1)	07/25/2023		C			1,119,729	(1)	(1)	Common Stock	140,190	\$0.00	0	I	By Versant Venture Capital V, L.P. ⁽²⁾
Series C Preferred Stock	(1)	07/25/2023		C			85,217	(1)	(1)	Common Stock	10,669	\$0.00	0	I	By Versant Venture Capital V (Canada) LP ⁽³⁾
Series C Preferred Stock	(1)	07/25/2023		C			37,283	(1)	(1)	Common Stock	4,667	\$0.00	0	I	By Versant Ophthalmic Affiliates Fund I, L.P. ⁽⁴⁾
Series C Preferred Stock	(1)	07/25/2023		C			33,682	(1)	(1)	Common Stock	4,216	\$0.00	0	I	By Versant Affiliates Fund V, L.P. ⁽⁵⁾
Series D Preferred Stock	(1)	07/25/2023		C			2,196,402	(1)	(1)	Common Stock	274,990	\$0.00	0	I	By Versant Vantage II, L.P. ⁽⁶⁾

Explanation of Responses:

1. Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.

2. Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein.

3. Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and

dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.

4. Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein.

5. Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein.

6. Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.

Remarks:

/s/ P. Joseph Campisi, Jr.,
Attorney-in-Fact

07/27/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.